Company intelligence / Profile preview
Deutsches Institut für Zell- und Gewebeersatz
- Ownership
- Private
- Development stage
- Other
Overview
DIZG is one of the largest non-profit pharmaceutical manufacturers in Germany specializing in allogeneic avital tissue transplants and autologous vital cell cultures. Since its founding in 1993, it has provided over 868,000 infection-free transplants across Germany and internationally. Its products are used primarily for patients with severe tissue defects, including burn victims and those requiring reconstructive surgery or treatment of chronic wounds. DIZG maintains an active R&D department focused on developing new transplant types and applications.
- Therapeutic areas
- DermatologyOther
- Modalities
- Cell therapyTissue transplant (allogeneic avital tissue transplants)Autologous cell cultures
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Deutsches Institut für Zell- und Gewebeersatz.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Deutsches Institut für Zell- und Gewebeersatz.